Novartis announces final agreement with Dr. Daniel Vasella
Basel, July 17, 2013 - The Novartis Board of Directors today announced a final agreement with its former Chairman, Dr. Daniel Vasella.
Since the Novartis Annual General Meeting (AGM), Dr. Daniel Vasella has provided certain transitional services, including select board mandates with subsidiaries of the company, to support the ad interim Chairman and the new Chairman who will assume office on August 1, 2013. For his services during this transition period, extending from the AGM on February 22, 2013, through October 31, 2013, Dr. Vasella will receive cash of CHF 2.7 million, and 31,724 unrestricted shares as of October 31, 2013 (the current market value of the shares is approximately CHF 2.2 million).
Dr. Vasella will subsequently be available to the company, at the company's request and discretion, to provide specific consulting services, such as the coaching of high potential associates of Novartis and speeches at key Novartis events. This consulting agreement is effective as of November 1, 2013, through the end of 2016. Dr. Vasella will be compensated at a rate of USD 25,000 per consulting day, with an annual guaranteed minimum fee of USD 250,000, for each of the calendar years 2014, 2015 and 2016.
"We are pleased that we will be able to call on Daniel Vasella's services and to have the opportunity to benefit from his knowledge and long-term experience in shaping a global healthcare leader," said Prof Dr. Ulrich Lehner, Novartis Chairman ad interim.
As announced previously, Dr. Vasella will hold the title as Honorary Chairman in recognition of his significant achievements on behalf of the company. There are no rights associated with this role in addition to his fiduciary duty as Honorary Chairman, and Dr. Vasella will not attend board meetings. No compensation will be provided in relation to this role other than administrative support and security which are usual and customary for a position of this nature.
This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "expects," or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the future.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 131,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
# # #
Novartis Media Relations
|Central media line : +41 61 324 2200|
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
Anja von Treskow
Novartis Global Media Relations
+41 61 324 8137 (direct)
+41 79 367 4723 (mobile)
e-mail: [email protected]
Novartis Investor Relations
|Central phone:||+41 61 324 7944|
|Samir Shah||+41 61 324 7944||North America:|
|Pierre-Michel Bringer||+41 61 324 1065||Stephen Rubino||+1 862 778 8301|
|Thomas Hungerbuehler||+41 61 324 8425||Jill Pozarek||+1 212 830 2445|
|Isabella Zinck||+41 61 324 7188||Edwin Valeriano||+1 212 830 2456|
|e-mail: [email protected]||e-mail: [email protected]|